Progress of primary mediastinal large B-cell lymphoma
10.3760/cma.j.cn115356-20210130-00028
- VernacularTitle:原发纵隔大B细胞淋巴瘤的研究进展
- Author:
Yating YU
1
;
Huaquan WANG
Author Information
1. 天津医科大学总医院血液科，天津 300052
- Keywords:
Mediastinal neoplasms;
Lymphoma, B-cell;
Diagnosis;
Immunotherapy;
Antineoplastic combined chemotherapy protocols;
Radiotherapy
- From:
Journal of Leukemia & Lymphoma
2021;30(10):637-640
- CountryChina
- Language:Chinese
-
Abstract:
Primary mediastinal large B-cell lymphoma (PMBCL) is an aggressive large B-cell lymphoma originating in the mediastinum. Because of its distinct clinical and histological features, PMBCL has been reclassified as a separate entity by the World Health Organization classification of lymphoid neoplasms. The diagnosis of PMBCL mainly depends on the pathological features, imaging examination and clinical features. Currently, there are many therapeutic schemes for PMBCL, the most commonly used schemes are R-CHOP and R-EPOCH regimens. Radiotherapy is beneficial in some patients, but it can also lead to long-term toxicity. Research and development of new drugs are ongoing, including chimeric antigen receptor T-cell therapy, anti-programmed death receptor 1 drugs, etc. PET-CT is mainly used to assess the curative effect after treatment and to guide the next treatment strategy.
